Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system.

Inclusion Criteria:

• ≥18 years of age
• Either diagnosis of breast cancer with plan for treatment according to the Keynote 522 regimen or non-small-cell lung cancer planned for neoadjuvant treatment that includes pembrolizumab
• Able to provide written informed consent

Exclusion Criteria:

• Pregnant or breast-feeding:
• Prior treatment with ICI therapy.
• Vulnerable patients, including pregnant women and prisoners
• Absolute Contraindication to rest/vasodilator stress PET/CT